Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 11, 2026

Surgeon almost goes broke on a $665K salary thanks to 1 sneaky financial fee. Ramit Sethi sets things straight

View original at finance.yahoo.com
Surgeon almost goes broke on a $665K salary thanks to 1 sneaky financial fee. Ramit Sethi sets things straight Ramit Sethi / Youtube Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • You want to pay a flat fee, never a percentage

    80% confidence
  • Projecting around 5.5% returns for 2024-2034 period

    80% confidence
  • Would happily pay a financial advisor for fixed-fee services like asset allocation review

    80% confidence
  • Some advisory fees can be negotiable

    80% confidence
  • Would never pay a percentage of assets under management

    80% confidence
  • Jeff and Susan's 1.24% AUM fee would cost them $863,170 over 35 years on their $460,000 portfolio

    80% confidence
  • If you feel bad about money at $50,000, you're probably going to feel that way when you make 10 times your income

    80% confidence
  • One asset will surge 400% in a year

    80% confidence
  • Nearly 50% of Americans are making 1 big Social Security mistake

    80% confidence
  • Forecasting 9% price returns from 2024 to 2034

    80% confidence
  • Generally feels most people are good and not trying to rip them off

    80% confidence
  • Financial advisor told her fee was roughly around 1% and downplayed its significance

    80% confidence
  • Most advisors make their money when portfolio grows, which is why they love older people and wealthy people who don't understand commission structures

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Surgeon almost goes broke on a $665K salary thanks to 1 sneaky financial fee. Ramit Sethi sets things straight — Source | Via News | Finance Via News